Wetwittayakhlang Panu, Golovics Petra A, Afif Waqqas, Bessissow Talat, Lakatos Peter L
Division of Gastroenterology, McGill University Health Center, Montreal, Canada.
Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
ACG Case Rep J. 2021 Nov 23;8(11):e00678. doi: 10.14309/crj.0000000000000678. eCollection 2021 Nov.
Tofacitinib is an oral Janus kinase inhibitor. Although it contributes to the induction and maintenance of clinical remission of patients with moderate-to-severe ulcerative colitis, various malignancies have been reported after the use of this small molecule. We report a rare case of biopsy-proven Kaposi sarcoma in a patient with complex biological-resistant ulcerative colitis after 2 years of treatment with tofacitinib. Kaposi sarcoma lesions spontaneously regressed after tofacitinib was discontinued. Given the concern of potential risk of malignancy associated with this agent, we believe that specialists should be aware of this rare but serious possible adverse event.
托法替布是一种口服的 Janus 激酶抑制剂。尽管它有助于诱导和维持中重度溃疡性结肠炎患者的临床缓解，但使用这种小分子药物后已报告了多种恶性肿瘤。我们报告了 1 例罕见病例，1 名患有复杂生物耐药性溃疡性结肠炎的患者在使用托法替布治疗 2 年后经活检证实发生了卡波西肉瘤。停用托法替布后，卡波西肉瘤病变自发消退。鉴于对该药物相关潜在恶性肿瘤风险的担忧，我们认为专科医生应意识到这种罕见但严重的可能不良事件。
